MAPT and Mental deterioration: The unresolved interplay between astrocytic pathways and protein aggregation underscores the need for targeted therapies that selectively modulate astrocyte functions, balancing neuroprotection and inflammation mitigation to address Aβ- or tau-driven cognitive decline.